Skip to content

Trial Summary

This study aims to evaluate the safety and preliminary efficacy of a drug called Avelumab in combination with chemotherapy plus radiotherapy (CRT) in patients with resectable oesophageal/ gastro-oesophageal junction (GOJ) adenocarcinoma.

Acronym:

NEOCREATE

ACTRN/NCT /ethics:

ACTRN12619000288123

Scientific title:

Neoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab – a Trial assessing feasibility and preliminary Efficacy

Sponsor / Cooperative group:

SA HEALTH

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream oesophageal/ gastro-oesophageal junction (GOJ) adenocarcinoma
Cancer StageEarly\In Situ
Anticipated Start Date2019-05-31
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Amitesh Roy
Recruitment StatusRecruiting
HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting
HospitalLyell McEwin hospital
Clinical Trial CoordinatorAndy Phay
Emailandy.phay@sa.gov.au
Phone08 8282 0833
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting